Inventiva (IVA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Buy Rating for Inventiva: Strategic Focus on Lanifibranor and Strong Financial Outlook
TipRanksFeb 14 12:35 ET · Ratings
LifeSci Capital Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsFeb 12 04:34 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Organon (OGN) and Inventiva (IVA)
TipRanksFeb 12 04:33 ET · Ratings
Stifel Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $17
Moomoo NewsFeb 11 07:31 ET · Ratings
Inventiva (IVA) Receives a Buy From Stifel Nicolaus
TipRanksFeb 11 07:07 ET · Ratings
Inventiva Reports €9.2M 2024 Revenues, €96.6M Cash As Of December 31, 2024; €116M Tranche Of €348M Financing Secured; Last Patient Screened For NATiV3 Phase 3 Lanifibranor Trial; Workforce Cut By 50% To Focus On Lanifibranor Development
BenzingaFeb 10 16:01 ET

Comments

Jaguar8

Jan 29 15:00

NEWS

$Inventiva (IVA.US)$
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
Wednesday, 29th January at 4:00 pm
• As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of t...

Jaguar8

Jan 22 23:28

🟤 Watchlist, JANUARY 23,2025, Thursday. NFA

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...

59

17

8

Jaguar8

Jan 22 15:00

NEWS

$Inventiva (IVA.US)$
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Wednesday, 22nd January at 4:00 pm
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfu...

Jaguar8

Dec 16, 2024 01:31

NEWS

$Inventiva (IVA.US)$
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Monday, 16th December at 2:30 am
◦ Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.

◦ Proceeds from the completed first tranche to be primarily used to advance Inventiva's ...

1

Trytosaveabit

Oct 30, 2024 15:07

News

$Inventiva (IVA.US)$ Inventiva Announces The Recommendation Of The Fifth DMC Of The NATiV3 Phase 3 Clinical Trial With Lanifibranor In Patients With MASH
Benzinga· 3 mins ago
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts,...

IVA Inventiva

Trade Overview

Capital Trend

News

Comments

Trending Stocks